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Articles
Cerebral microbleeds and intracranial haemorrhage risk in 
patients anticoagulated for atrial fibrillation after acute 
ischaemic stroke or transient ischaemic attack (CROMIS-2): 
a multicentre observational cohort study
Duncan Wilson, Gareth Ambler, Clare Shakeshaft, Martin M Brown, Andreas Charidimou, Rustam Al-Shahi Salman, Gregory Y H Lip, 
Hannah Cohen, Gargi Banerjee, Henry Houlden, Mark J White, Tarek A Yousry, Kirsty Harkness, Enrico Flossmann, Nigel Smyth, Louise J Shaw, 
Elizabeth Warburton, Keith W Muir, Hans Rolf Jäger, David J Werring, on behalf of the CROMIS-2 collaborators*
Summary
Background Cerebral microbleeds are a potential neuroimaging biomarker of cerebral small vessel diseases that are 
prone to intracranial bleeding. We aimed to determine whether presence of cerebral microbleeds can identify patients 
at high risk of symptomatic intracranial haemorrhage when anticoagulated for atrial fibrillation after recent ischaemic 
stroke or transient ischaemic attack.
Methods Our observational, multicentre, prospective inception cohort study recruited adults aged 18 years or older 
from 79 hospitals in the UK and one in the Netherlands with atrial fibrillation and recent acute ischaemic stroke or 
transient ischaemic attack, treated with a vitamin K antagonist or direct oral anticoagulant, and followed up for 
24 months using general practitioner and patient postal questionnaires, telephone interviews, hospital visits, and 
National Health Service digital data on hospital admissions or death. We excluded patients if they could not undergo 
MRI, had a definite contraindication to anticoagulation, or had previously received therapeutic anticoagulation. The 
primary outcome was symptomatic intracranial haemorrhage occurring at any time before the final follow-up at 
24 months. The log-rank test was used to compare rates of intracranial haemorrhage between those with and without 
cerebral microbleeds. We developed two prediction models using Cox regression: first, including all predictors 
associated with intracranial haemorrhage at the 20% level in univariable analysis; and second, including cerebral 
microbleed presence and HAS-BLED score. We then compared these with the HAS-BLED score alone. This study is 
registered with ClinicalTrials.gov, number NCT02513316.
Findings Between Aug 4, 2011, and July 31, 2015, we recruited 1490 participants of whom follow-up data were available for 
1447 (97%), over a mean period of 850 days (SD 373; 3366 patient-years). The symptomatic intracranial haemorrhage rate 
in patients with cerebral microbleeds was 9·8 per 1000 patient-years (95% CI 4·0–20·3) compared with 2·6 per 
1000 patient-years (95% CI 1·1–5·4) in those without cerebral microbleeds (adjusted hazard ratio 3·67, 95% CI 
1·27–10·60). Compared with the HAS-BLED score alone (C-index 0·41, 95% CI 0·29–0·53), models including cerebral 
microbleeds and HAS-BLED (0·66, 0·53–0·80) and cerebral microbleeds, diabetes, anticoagulant type, and HAS-BLED 
(0·74, 0·60–0·88) predicted symptomatic intracranial haemorrhage significantly better (difference in C-index 0·25, 
95% CI 0·07–0·43, p=0·0065; and 0·33, 0·14–0·51, p=0·00059, respectively).
Interpretation In patients with atrial fibrillation anticoagulated after recent ischaemic stroke or transient ischaemic 
attack, cerebral microbleed presence is independently associated with symptomatic intracranial haemorrhage risk 
and could be used to inform anticoagulation decisions. Large-scale collaborative observational cohort analyses are 
needed to refine and validate intracranial haemorrhage risk scores incorporating cerebral microbleeds to identify 
patients at risk of net harm from oral anticoagulation.
Funding The Stroke Association and the British Heart Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Atrial fibrillation increases the risk of ischaemic stroke 
by five times.1 In most individuals, oral anticoagulation 
with either vitamin K antagonists (VKAs) or direct oral 
anticoagulants (DOACs) is indicated because they reduce 
the risk of ischaemic stroke by about two thirds, with 
only a minimal increase in extracranial haemorrhage.2,3 
However, a devastating and unpredictable complication 
of oral anticoagulation is symptomatic intracranial 
haemorrhage, which has 42% in-hospital mortality and 
causes substantial disability in survivors.4 There is an 
unmet clinical need to reliably predict the risk of 
intracranial haemorrhage and to differentiate this from 
the risk of ischaemic stroke, to allow clinicians to assess 
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the likely net clinical benefit of oral anticoagulation. Risk 
scores including clinical factors (eg, hypertension and 
age) have been developed to identify patients at high 
risk of bleeding on anticoagulation—including the 
HAS-BLED,5 HAEMORR2HAGES,6 and ATRIA7 scores—
but these are of limited value in clinical decision making 
because they do not differentiate between prediction of 
ischaemic stroke and of intracranial haemorrhage.
Cerebral microbleeds are small, hypointense, round or 
ovoid areas identified on blood-sensitive MRI sequences 
(T2*-weighted gradient-recalled echo [GRE] or suscep- 
tibility-weighted imaging).8,9 In most cases, cerebral 
microbleeds correspond pathologically to small clusters of 
haemosiderin-laden macrophages resulting from small 
self-limiting haemorrhages.10,11 Thus, cerebral microbleeds 
are a promising radiological biomarker of the cerebral 
small vessel diseases that are prone to bleeding and cause 
most spontaneous intracerebral haemorrhages,9 so might 
be a specific and clinically useful predictor of 
anticoagulant-related intracranial haemorrhage. With the 
increasing use of blood-sensitive MRI, cerebral 
microbleeds can be detected in about 30% of patients with 
ischaemic stroke and atrial fibrillation,12 generating 
uncertainty about the risk–benefit balance of 
anticoagulation in patients with cerebral microbleeds.
We did an observational, prospective, multicentre, 
inception cohort study to determine whether cerebral 
microbleeds are independently associated with an 
increased risk of symptomatic intracranial haemorrhage in 
patients with recent acute ischaemic stroke or transient 
ischaemic attack with atrial fibrillation treated with 
anticoagulation. We developed and internally validated 
risk prediction scores for symptomatic intracranial 
haemorrhage including cerebral microbleed presence as a 
neuroimaging biomarker in addition to clinical risk factors.
Methods
Study design and participants
CROMIS-2 is an observational, multicentre, prospective, 
inception cohort study that recruited adults (ie, ≥18 years 
Research in context
Evidence before this study
We searched MEDLINE without language restrictions for 
publications regarding cerebral microbleeds, atrial fibrillation, 
and ischaemic stroke published from inception up to 
Nov 3, 2017. We used the search terms (Cerebral 
microbleed*.mp OR microbleed.mp) AND (atrial fibrillation/ OR 
anticoagula*.mp OR anticoagula* OR warfarin.mp OR 
rivaroxaban.mp OR apixaban.mp OR edoxaban.mp OR 
dabigatran.mp) AND (cerebral infarction/ OR brain ischemia/ or 
stroke/ or isch?emi*.mp/ or transient isch?emic attack). We 
found four published prospective studies that reported rates of 
intracerebral haemorrhage in relation to baseline cerebral 
microbleeds in patients with ischaemic stroke or transient 
ischaemic attack treated with anticoagulation for atrial 
fibrillation. The largest study, involving 550 patients from 
Korea, showed a significant association between cerebral 
microbleed presence and intracerebral haemorrhage after 
adjusting for age, sex, and previous haemorrhagic stroke 
(hazard ratio [HR] 3·8; 95% CI 1·1–13·1), but none of the other 
studies were sufficiently powered to confirm this association. 
A post-hoc aggregate data meta-analysis of data mainly from 
small retrospective and prospective cohorts, with variable 
completeness and follow-up duration, suggested that cerebral 
microbleeds are associated with increased intracerebral 
haemorrhage risk, but could not adjust for confounding factors 
or develop risk models for intracranial haemorrhage.
Added value of this study
Our observational, predominantly UK-based, multicentre, 
prospective inception cohort study including 3366 patient-
years of follow-up was designed and powered to determine 
whether cerebral microbleeds are independently associated 
with a higher risk of intracranial haemorrhage in patients with 
recent acute ischaemic stroke or transient ischaemic attack 
associated with atrial fibrillation and started for the first time 
on oral anticoagulation. We provide new evidence that in 
patients with ischaemic stroke or transient ischaemic attack 
and atrial fibrillation, cerebral microbleed presence is an 
independent risk factor for intracranial haemorrhage. We also 
show that the risk of intracranial haemorrhage increases as 
cerebral microbleed burden increases, but that the absolute 
event rate for ischaemic stroke remains higher than that of 
intracranial haemorrhage, even in patients with multiple 
cerebral microbleeds. We developed and internally validated a 
simple risk prediction score for intracranial haemorrhage, 
showing for the first time that the inclusion of cerebral 
microbleed presence as a neuroimaging biomarker improves 
the predictive value of a commonly used bleeding risk score 
based on clinical data alone (the HAS-BLED score).
Implications of all the new evidence
Our study provides proof of concept that including a 
neuroimaging biomarker (cerebral microbleeds) improves 
the predictive ability of clinical risk scores for intracranial 
haemorrhage—a potentially deadly complication of oral 
anticoagulation—which could help clinicians and patients to 
make better informed anticoagulation decisions. Our findings 
support further pooled meta-analyses of individual participant 
data from large prospective cohorts to increase the precision of 
risk estimates for intracranial haemorrhage, to determine 
whether high cerebral microbleed counts can identify patients 
who will experience net harm from oral anticoagulation, and to 
refine and validate intracranial haemorrhage risk scores 
incorporating clinical and neuroimaging factors including 
cerebral microbleeds.
Articles
www.thelancet.com/neurology   Vol 17   June 2018 541
of age) with electrocardiogram-confirmed non-valvular 
atrial fibrillation who presented to one of 80 participating 
hospitals (79 in the UK and one in the Netherlands) with 
ischaemic stroke or transient ischaemic attack and were 
identified by their treating physician for anticoagulation 
treatment. We did not strictly control the timing of oral 
anticoagulation, which depended on best clinical 
judgment according to standard practice. We excluded 
patients if they could not undergo MRI, had a definite 
contraindication to anticoagulation, or had previously 
received therapeutic anticoagulation.
CROMIS-2 was approved by the UK National Health 
Service Research Ethics Committee. Patients with 
capacity gave informed written consent. When patients 
could not consent, we obtained written informed consent 
from a proxy as defined by relevant local legislation.
Procedures
All patients underwent baseline brain MRI according to a 
predefined protocol parameter range, designed to detect 
relevant markers of cerebrovascular disease13 
(see appendix), which required T2*-weighted GRE 
(echo time 10–45 ms), axial T1-weighted, axial T2-weighted, 
coronal fluid-attenuated inversion recovery, and diffusion-
weighted imaging with apparent diffusion coefficient 
maps. MRIs were analysed for markers of cerebral small 
vessel disease defined according to consensus definitions9 
using validated scales where available. We used the 
Microbleed Anatomical Rating Scale14 to identify and 
classify cerebral microbleeds as lobar or non-lobar 
(ie, deep, including the basal ganglia, thalamus, deep 
white matter, brainstem, and cerebellum). We rated white 
matter hyperintensities using the Fazekas and age-related 
white matter changes (ARWMC) scales,15,16 and defined 
cortical superficial siderosis using consensus criteria.17–19 
All neuroimaging ratings were done by a clinical research 
fellow (DW) trained by a professor of neuroradiology with 
cerebrovascular expertise (HRJ). A second trained clinical 
research fellow (GB) rated a random 10% sample for 
cerebral microbleed presence; we quantified intra-rater 
and inter-rater reliability for cerebral microbleed presence 
using Cohen’s κ coefficient.
We obtained screening logs to assess selection bias. We 
obtained detailed clinical and demographic baseline data. 
From these data we calculated CHA₂DS₂VASc and HAS-
BLED scores, designed to predict the risks of ischaemic 
stroke and major bleeding, respectively, in patients with 
non-valvular atrial fibrillation. We obtained follow-up 
information from patients and general practitioners at 
6 months, 12 months, and 24 months via standardised 
structured postal questionnaires or telephone interviews. 
We obtained National Health Service digital data 
regarding hospital admissions or death during follow-up. 
For reported outcome events, we obtained additional 
clinical and radiological details from treating clinical 
teams and medical records to allow central adjudication, 
blinded to baseline neuroimaging findings.
Outcomes
The primary outcome was symptomatic intracranial 
haemorrhage, defined as brain-imaging evidence of non-
traumatic spontaneous intracranial haemorrhage with 
appropriate clinical symptoms, at any time before the 
final follow-up at 24 months. The secondary outcomes 
were recurrent ischaemic stroke and death of any cause. 
Further secondary outcomes not reported in this paper 
were transient ischaemic attack, cardiac ischaemic events 
(defined by dynamic electrocardiogram changes or 
troponin rise), subdivisions of intracranial haemorrhage 
(intracerebral [reported], subarachnoid, subdural, and 
extradural haemorrhage), major bleeding (defined as 
intracranial bleeding or extracranial bleeding in either a 
critical area or requiring hospitalisation and two units of 
blood transfusion20), quality of life, and long-term physical 
disability. A composite outcome of death, ischaemic 
stroke, and symptomatic inracranial haemorrhage was 
prespecified by the Steering Committee prior to the end 
of recruitment and data analysis, but was not prespecified 
in the statistical analysis plan. 
Two professors of vascular neurology (DJW and MMB) 
and a clinical research fellow (DW) adjudicated all 
primary outcome events. A trained clinical research 
fellow (DW) adjudicated all ischaemic stroke outcomes; a 
random 10% of these were adjudicated by a professor 
of vascular neurology (DJW) and a professor of 
neuroradiology (HRJ). All adjudication was blinded to 
baseline cerebral microbleed ratings. In cases of 
disagreement, we reached consensus after discussion.
Statistical analysis
We followed a prespecified published statistical analysis 
plan, which is provided in full in the appendix. We 
calculated a planned sample size of 1425 participants to 
detect a relative risk of 4·0 for intracranial haemorrhage 
associated with cerebral microbleeds, assuming an annual 
incidence of intracranial haemorrhage of 1·25% in those 
without cerebral microbleeds and that 20% of our 
population would have cerebral microbleeds; these 
estimates were derived from previous smaller studies.13 
We included patients in the final analysis if they had 
undergone MRI with T2*-weighted GRE sequences of 
adequate technical quality to rate cerebral microbleeds.
We compared baseline demographics and risk factor 
profiles between those with and without cerebral 
microbleeds, and between those with and without 
our primary outcome event (symptomatic intracranial 
haemorrhage). We used appropriate statistical measures 
for categorical and continuous measures. We visually 
inspected the distributions of continuous variables using 
histograms, summarised as means with SDs or medians 
with IQRs. Groups were compared using the 
Mann-Whitney U test if not normally distributed or the 
t test if normally distributed; categorical variables 
were compared between groups with the χ² test or, 
where appropriate, Fisher’s exact test. Univariate 
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Kaplan-Meier survival probabilities were estimated for 
those with and without cerebral microbleeds; we used the 
log-rank test to compare groups. We did univariable and 
multivariable Cox regression (adjusted for age and history 
of hypertension, as documented in our statistical analysis 
plan). We did three further multivariable Cox regression 
sensitivity analyses: first, including variables strongly 
associated with intracranial haemorrhage in univariate 
analysis; second, including cerebral microbleed presence 
and the HAS-BLED clinical bleeding risk score;21 and 
third, including cerebral microbleed presence and other 
neuroimaging markers of small vessel disease. We 
assessed the proportional hazards assumption through 
visual inspection of log-log plots of the log cumulative 
hazard against log time. We calculated absolute event 
rates per 1000 patient-years for the primary and the main 
secondary outcomes. For recurrent ischaemic stroke 
multivariable analysis, we adjusted for variables that 
differed between those with and without recurrent 
ischaemic stroke at the 20% level.
We developed two prediction models using Cox 
regression: first, including all predictors associated with 
intracranial haemorrhage at the 20% level in univariable 
analysis; and second, including cerebral microbleed 
presence and HAS-BLED score. We assessed calibration 
using the Cox calibration slopes, and quantified 
discrimination using Harrell’s C-index. For bootstrapping 
validation, the models were re-fitted in 1000 bootstrap 
samples and applied to the original dataset. For each 
model, we then calculated the calibration slope and 
optimism-adjusted C-index.22 We also fitted these models 
using the lasso method23 to investigate possible 
overfitting. We did all statistical analysis using Stata 
version 12.0.
This study is registered with ClinicalTrials.gov, number 
NCT02513316.
Role of the funding source
Neither the funders nor the sponsor had input into study 
design; data collection, data analysis, data interpretation; 
writing of the report; or the decision to submit the paper 
for publication. The corresponding author had full access 
to all the data in the study and had final responsibility for 
the decision to submit for publication.
Results 
Between Aug 3, 2011, and July 31, 2015, 1686 potentially 
eligible patients consented from 79 centres across the UK 
and one centre in the Netherlands. After neuroimaging 
quality assurance, our final analysis included 
1490 participants (1294 [87%] with 1·5 Tesla and 
196 [13%] with 3 Tesla MRI scans); patient flow through 
the study is shown in figure 1. We found no significant 
differences in demographics, stroke risk factors, or 
stroke severity between patients included in the final 
analysis compared with those who gave consent and 
were screened but were ineligible or excluded. We 
collected screening logs from 26 sites (1120 patients) to 
assess selection bias; compared with the 506 patients 
who were included in the final analysis, the 614 patients 
who were eligible but did not consent were older (mean 
age 80 years [SD 11] vs 75 years [10]; p<0·0001), more 
likely to be female (252 [55%] of 460 patients vs 
213 [42%] of 506 patients; p<0·0001), and had more 
severe strokes (median baseline National Institutes of 
Health Stroke Score 8 [IQR 3–16] vs 5 [2–10], p<0·0001).
Of 1490 patients included, 1447 (97%) had follow-up 
information available from any time during the 
24 months (figure 1). The 43 patients without follow-up 
did not differ from those with follow-up in age 
(76 years [SD 10] vs 73 years [11]; p=0·166), hypertension 
(23 [58%] of 40 patients vs 907 [64%] of 1427 patients; 
p=0·43), or cerebral microbleed prevalence (seven [16%] of 
43 patients vs 304 [21%] of 1447 patients; p=0·452).
Cerebral microbleeds were present in 311 (21%) of 
1490 participants included in the final analyses, with a 
median cerebral microbleed count of one (IQR 1–3; 
table 1). Intra-rater and inter-rater reliability for the 
presence of cerebral microbleeds were excellent 
(intra-rater κ 0·93, 95% CI 0·86–1·00 and inter-rater 0·85, 
0·74–0·96). Cerebral microbleeds were strictly lobar in 116 
patients, strictly non-lobar (deep) in 120 patients, and 
mixed in 75 patients. 46 (3%) patients fulfilled the 
modified Boston criteria for cerebral amyloid angiopathy.18 
Cortical superficial siderosis was identified in five patients, 
of which one was considered to be disseminated (table 1). 
Figure 1: Participant flow
1686 participants assessed for eligibility
1496 with appropriate MRI imaging available
            for analysis
1490 included in final analyses
1447 included in survival analysis at 24 months
190 not eligible
 114 MRI not done
 76 MRI done but did not meet protocol 
  specifications
  49 no T2* gradient-recalled echo
  18 inadequate encryption or 
       anonymisation
   9 incorrect date or patient details
6 excluded from final analysis
 3 echo time too low
 3 T2* gradient-recalled echo of poor 
        quality due to motion artifact
43 lost to follow-up
Articles
www.thelancet.com/neurology   Vol 17   June 2018 543
432 (29%) patients had severe white matter hyperintensities 
(ARWMC score15 ≥2 in either basal ganglia or white matter 
regions).
The 1447 patients with follow-up data available 
provided 3366 patient-years of follow-up data (mean 
follow-up 850 days, SD 373). In this population, 
there were 14 symptomatic intracranial haemorrhages: 
11 intracerebral haemorrhages, two subdural haemo- 
rrhages, and one subarachnoid haemorrhage. Compared 
with those who remained free of intracranial haemorrhage, 
patients who had a symptomatic intracranial haemorrhage 
during follow-up had a higher prevalence of diabetes, were 
more likely to have been treated with a VKA than a DOAC, 
and more likely to have cerebral microbleeds and cortical 
superficial siderosis (table 2). In the seven patients with a 
documented international normalised ratio at the time of 
the intracranial haemorrhage, the median international 
normalised ratio was 1·9 (IQR 1·4–4·0, range 1·1–4·8).
The symptomatic intracranial haemorrhage event rate 
in patients with cerebral microbleeds was 9·8 per 
1000 patient-years (95% CI 4·0–20·3) compared with 
2·6 per 1000 patient-years (95% CI 1·1–5·4) in those 
without cerebral microbleeds; the absolute rate increase 
associated with cerebral microbleeds was 7·2 per 
1000 patient-years (95% CI 2·9–14·9; table 3).
Using the log-rank test for equality of survivor 
functions, we found that symptomatic intracranial 
haemorrhages were more frequent in patients with 
cerebral microbleeds compared with those without 
(p=0·0081). In univariable Cox regression, the hazard of 
sympto matic intracranial haemorrhage for patients with 
cerebral microbleeds was more than three times 
higher than that for patients without cerebral micro-
bleeds; this risk was maintained in multivariable Cox 
regression analysis adjusted for hypertension and age 
(figure 2; table 3). The risk of symptomatic intracranial 
haemorrhage increased with increasing cerebral 
microbleed burden (overall p=0·017 from adjusted Cox 
regression for categories 0, 1, and ≥2 cerebral microbleeds 
and overall p=0·032 from unadjusted Cox regression for 
categories 0, 1, 2–4, and ≥5 cerebral microbleeds; table 3; 
appendix). We explored cerebral microbleed distribution 
and rates of symptomatic intracranial haemorrhage, but 
there were too few events within each category to draw 
reliable conclusions (appendix).
Of the 1490 patients recruited and identified to start 
anticoagulation, 1436 (96%) did so (table 1); 54 patients did 
not start because 12 had died, 13 refused or did not attend 
their anticoagulation clinic appointments, 17 had medical 
contraindications, and for 12 patients the reason was not 
specified. The median time from stroke symptoms until 
starting anticoagulation was 11 days (IQR 4–17); 
894 (60%) of 1490 patients started a VKA and 542 (36%) of 
1490 patients started a DOAC. Repeat analyses including 
only the 1436 anticoagulated participants did not affect our 
main result (univariable hazard ratio [HR] for cerebral 
microbleed presence 3·73; 95% CI 1·31–10·63). The type 
of anticoagulant (DOAC or VKA) did not significantly 
affect the hazard of symptomatic intracranial haemorrhage 
associated with cerebral microbleed presence (HR 
interaction term 0·88; 95% CI 0·04–17·13 p=0·92).
There were 56 recurrent ischaemic strokes during 
3312 patient-years of follow-up. We observed an increased 
ischaemic stroke rate of 9·1 per 1000 patient-years 
(95% CI 3·5–18·3) associated with cerebral microbleeds 
(table 3). However, cerebral microbleed presence was not 
associated with recurrent ischaemic stroke in univariable 
or multivariable analyses (table 3; appendix). Mortality 
following symptomatic intracranial haemorrhage during 
All patients 
(n=1490)
Patients with 
cerebral microbleeds 
(n=311)
Patients without 
cerebral microbleeds 
(n=1179)
Age, years 76 (10) 78 (10) 75 (10)
Sex
Female 631 (42%) 129 (41%) 502 (43%)
Male 859 (58%) 182 (59%) 677 (57%)
Hypertension 930/1467 (63%) 212/303 (70%) 718/1164 (62%)
Hyperlipidaemia 661/1469 (45%) 145/307 (47%) 516/1162 (44%)
Diabetes 251 (17%) 55 (18%) 196 (17%)
Ischaemic heart disease 243 (16%) 66 (21%) 177 (15%)
Previous ischaemic stroke 142 (10%) 41 (13%) 101 (9%)
Previous intracerebral haemorrhage 8 (1%) 3 (1%) 5 (<1%)
Alcohol use
Units per week 2 (0–9) 2 (0–7) 2 (0–10)
>14 units per week 213/1384 (15%) 43 (15%) 170/1092 (16%)
Congestive heart failure 60 (4%) 20 (6%) 40 (3%)
Abnormal renal function 174 (12%) 46 (15%) 128 (11%)
Ethnicity
White 1414 (95%) 290 (95%) 1124 (95%)
Asian* 33 (2%) 10 (3%) 23 (2%)
Black 20 (1%) 5 (2%) 15 (1%)
C-reactive protein, mg/L 4·6 (2·0–12·0) 4·4 (2·0–12·0) 4·9 (2·0–11·2)
Platelet count 221 (185–265) 221 (185–265) 222 (183–265)
HAS-BLED score 3 (2–3) 3 (2–4) 3 (3–4)
CHA2DS2VASc score 5 (4–6) 5 (4–6) 5 (4–6)
Anticoagulation started 1436 (96%) 300 (96%) 1136 (96%)
Anticoagulant used
DOAC 542/1436 (37%) 121/300 (40%) 421/1136 (37%)
VKA 894/1436 (62%) 179/300 (60%) 715/1136 (63%)
Concurrent antiplatelet use 57/894 (6%) 9 (3%) 48 (4%)
Poor time in therapeutic range† 133/894 (15%) 24/179 (13%) 109/715 (15%)
Anticoagulation stopped during 
follow-up
55/1436 (4%) 13/300 (4%) 42/1136 (4%)
Total white matter hyperintensity 
(ARWMC) score
1 (0–3) 2 (1–4) 1 (0–3)
Cerebral microbleeds ·· 1 (1–3); 
range 1–107
NA
cSS presence 5 (<1%) 1 (<1%) 4 (<1%)
Data are n (%), n/N (%), mean (SD), or median (IQR). DOAC=direct oral anticoagulant; cSS=cortical superficial siderosis. 
ARWMC=age-related white matter changes. NA=not applicable. VKA=vitamin K antagonist. *Asian denotes Indian, 
Pakistani, Bangladeshi, or “any other Asian background”.†Poor time in therapeutic range for VKA use was defined as <60%.
Table 1: Baseline characteristics
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follow-up was higher than that of recurrent ischaemic 
stroke (seven [50%, 95% CI 23–77] of 14 patients vs 
12 [21%, 12–34] of 56 patients; p=0·041). In multivariable 
analysis, when adjusting for age and hypertension, 
cerebral microbleed presence was associated with 
symptomatic intracerebral haemorrhage (HR 4·24; 95% CI 
1·27–14·08) but not death or the composite outcome 
(appendix).
In the first prediction model, we included variables that 
were significant at the 20% level in univariable analyses: 
cerebral microbleed presence, diabetes, DOAC use, and 
HAS-BLED score. We excluded cortical superficial 
siderosis owing to its rarity, and time in therapeutic 
range for VKA because it is captured within HAS-BLED. 
Missing alcohol scores for HAS-BLED were imputed 
using multiple imputation with chained equations24 
(ten imputations). Fitting a model with all four predictors 
(cerebral microbleed presence, diabetes, DOAC use, and 
HAS-BLED score) produced an optimism-adjusted 
C-index of 0·74 (95% CI 0·60–0·88). In the second 
model, we included cerebral microbleed presence and 
HAS-BLED score (imputed as above), which produced an 
optimism-adjusted C-index of 0·66 (95% CI 0·53–0·80; 
see appendix for Cox calibration slopes). Compared with 
the HAS-BLED score alone (C-index 0·41; 95% CI 
0·29–0·53), the first model (C-index difference 0·33, 
0·14–0·51; p=0·00059) and the second model (C-index 
difference 0·25, 0·07–0·43; p=0·0065) were both better 
in predicting symptomatic intracranial haemorrhage.
We undertook three sensitivity analyses to confirm a 
robust independent association of cerebral microbleed 
presence with symptomatic intracranial haemorrhage. 
Because we observed only 14 symptomatic intracranial 
haemorrhages, we included a maximum of two predictor 
variables in each analysis. Cerebral microbleed presence 
remained an independent predictor of intracranial 
haemorrhage as follows: first, when adjusted for the 
two strongest univariable predictors (diabetes and 
anticoagulant type, but not cortical superficial siderosis 
because of its rarity): HR 3·63; 95% CI 1·27–10·38; 
second, when adjusted for HAS-BLED score: 
5·64, 1·79–17·80; and third, when adjusted for other 
neuroimaging markers of small vessel disease: HR 
adjusted for total age-related white matter hyperintensities 
score 3·69, 1·26–10·74; HR adjusted for any cortical 
superficial siderosis 4·12, 1·42–11·97 (appendix). For each 
model, visual inspection of the log-log plots suggested that 
the proportional hazards assumption was satisfactory.
Discussion
Our prospective, observational, multicentre cohort of 
patients anticoagulated after recent ischaemic stroke or 
transient ischaemic attack associated with atrial 
fibrillation shows that baseline cerebral microbleed 
presence is independently associated with an increased 
risk of symptomatic intracranial haemorrhage, but not of 
recurrent ischaemic stroke. However, the absolute rate of 
recurrent ischaemic stroke was much higher than the 
absolute rate of intracranial haemorrhage, even in those 
with cerebral microbleeds. We also show that the addition 
of a neuroimaging biomarker (cerebral microbleed 
presence) improves the predictive ability of a clinical 
bleeding risk score (HAS-BLED), which could help 
clinicians better identify patients at high risk of 
intracranial haemorrhage.
Our results are consistent with a smaller hospital-based 
cohort study in Korea of 550 patients with ischaemic 
Patients with 
symptomatic intracranial 
haemorrhage (n=14)
Patients without 
symptomatic intracranial 
haemorrhage (n=1433)
p value
Age, years 79 (10) 76 (10) 0·322
Sex ·· ·· 0·620
Female 5 (36%) 606 (42%) ··
Male 9 (64%) 827 (58%) ··
Hypertension 8 (57%) 898/1411 (64%) 0·615
Hyperlipidaemia 8 (57%) 629/1413 (45%) 0·344
Diabetes 6 (43%) 236 (16%) 0·0086
Ischaemic heart disease 1 (7%) 238 (17%) 0·343
Previous ischaemic stroke 2 (14%) 138 (10%) 0·500
Previous intracerebral haemorrhage 0 8 (1%) 1·0
Alcohol use
Units per week 1·5 (0·0–5·0) 2 (0–9) 0·515
>14 units per week 1/12 (8%) 205/1339 (15%) 0·496
Congestive heart failure 0 59 (4%) 0·440
Abnormal renal function 2 (14%) 169 (12%) 0·774
Ethnicity
White 14 (100%) 1356 (95%) ··
Non-white 0 46 (3%) 0·492
Asian* 0 29 (2%) ··
Black 0 17 (1%) ··
C-reactive protein, mg/L 5·5 (4·6–16·2) 4·4 (2·0–12·0) 0·113
Platelet count 212 (167–225) 220 (185–264) 0·252
CHA2DS2VASc score 6 (4–6) 5 (4–6) 0·224
HAS-BLED score 2 (2–3) 3 (2–3) 0·144
Anticoagulation started 14 (100%) 1385 (97%) 0·485
Anticoagulant used ·· ·· 0·071
DOAC 2 (14%) 523/1385 (38%) ··
VKA 12 (86%) 862/1385 (62%) ··
Concurrent antiplatelets 1 (7%) 56 (4%) 0·536
Poor time in therapeutic range† 0 133/862 (15%) 0·145
Total white matter hyperintensity 
(ARWMC) score
1·5 (0·0–5·0) 1 (0·0–3·0) 0·968
Cerebral microbleed presence 7 (50%) 297 (21%) 0·0075
Median 0·5 (0·0–3·0) 0 (0·0–0·0) 0·0034
Range 0–12 0–107 NA
cSS presence 1 (7%) 4 (<1%) <0·0001
Data are n (%), n/N (%), mean (SD), or median (IQR). Follow-up was at any time during the 24 months after enrolment, 
with a minimum of 6 months. DOAC=direct oral anticoagulant. cSS=cortical superficial siderosis. ARWMC=age-related 
white matter changes. NA=not applicable. VKA=vitamin K antagonist. *Asian denotes Indian, Pakistani, Bangladeshi, 
or “any other Asian background”.†Poor time in the therapeutic range for VKA use was defined as <60%.
Table 2: Characteristics of patients with and without symptomatic intracranial haemorrhage at follow-up
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stroke and atrial fibrillation25 that reported an increased 
risk of intracerebral haemorrhage associated with 
cerebral microbleeds (HR 3·8, 95% CI 1·1–13·1), as well 
as with a recent aggregate data meta-analysis.12 Our 
finding that diabetes is independently associated with 
symptomatic intracranial haemorrhage has not, to the 
best of our knowledge, been previously reported in 
ischaemic stroke cohorts. However, a large community-
based study reported that diabetes was associated with 
intracerebral haemorrhage risk (1·59, 1·26–2·02),26 
whereas another study27 of older patients (≥75 years of 
age; median age 82 years) with atrial fibrillation attending 
an anticoagulation clinic found an association between 
diabetes and major bleeding (mostly intracranial 
haemorrhage; odds ratio 4·4, 95% CI 1·3–14·7).
Our finding that cerebral microbleed presence was not 
associated with recurrent ischaemic stroke differs from 
our recent meta-analysis28 of patients with recent 
ischaemic stroke or transient ischaemic attack, probably 
because the meta-analysis included mostly patients 
without atrial fibrillation and treated with antiplatelet 
therapy. The association of cerebral microbleed presence 
with future symptomatic intracranial haemorrhage but 
not ischaemic stroke risk in our cohort supports the 
hypothesis that cerebral microbleeds are a neuroimaging 
biomarker of a bleeding-prone arteriopathy specifically 
relevant for intracranial haemorrhage associated with 
anticoagulation. However, the relationship between 
cerebral microbleed presence and recurrent ischaemic 
stroke risk, while not statistically significant, also 
favoured a positive association. Thus, cerebral micro-
bleeds, as a marker of overall vascular fragility, might not 
reliably discriminate between intracranial bleeding and 
ischaemic stroke risks, but this important question 
requires further study. Indeed, the absolute event rate of 
ischaemic stroke in patients with cerebral microbleeds 
(24·1 per 1000 patient-years) was much higher than the 
absolute event rate of symptomatic intracranial 
haemorrhage (9·8 per 1000 patient-years). By contrast 
with cerebral microbleeds, white matter hyperintensities 
were not associated with symptomatic intracranial 
haemorrhage in our study, in keeping with data from two 
previous smaller similar cohort studies.25,29
Although recent meta-analyses of ischaemic stroke and 
transient ischaemic attack cohorts have explored the risk 
of intracerebral haemorrhage in patients with five or 
more cerebral microbleeds,12,28 we did not present hazard 
ratios for this subgroup because of the very low number 
of participants with high cerebral microbleed counts and 
of symptomatic intracranial haemorrhage events, which 
could lead to statistically unreliable results and 
Figure 2: Probability of symptomatic intracranial haemorrhage according to the presence or absence of 
cerebral microbleeds
The hazard ratio (HR) and 95% CI are derived from the model adjusted for hypertension and age.
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Adjusted hazard ratio 3·67 (95% CI 1·27–10·60); p=0·016
Absolute 
event rate*
Rate per 1000 patient-
years (95% CI)
Absolute rate increase per 
1000 patient-years (95% CI)
Univariable hazard 
ratio (95% CI)
Adjusted hazard 
ratio (95% CI)†
Symptomatic intracranial haemorrhage
No cerebral microbleeds 7/2654 2·6 (1·1 to 5·4) 1 (ref) 1 (ref) 1 (ref)
Cerebral microbleeds present 7/712 9·8 (4·0 to 20·3) 7·2 (2·9 to 14·9) 3·73 (1·31 to 10·64) 3·67 (1·27 to 10·60)
1 cerebral microbleed 2/367 5·4 (0·7 to 19·7) 2·8 (−0·4 to 14·3) 2·04 (0·42 to 9·84) 2·03 (0·42 to 9·83)
≥2 cerebral microbleeds 5/345 14·4 (4·7 to 33·8) 11·8 (3·6 to 28·4) 5·58 (1·77 to 17·58) 5·46 (1·70 to 17·51)
Recurrent ischaemic stroke
No cerebral microbleeds 39/2608 15·0 (10·6 to 20·4) 1 (ref) 1 (ref) 1 (ref)
Cerebral microbleeds present 17/704 24·1 (14·1 to 38·7) 9·1 (3·5 to 18·3) 1·62 (0·92 to 2·87) 1·53 (0·85 to 2·76)
1 cerebral microbleed 9/362 24·9 (11·4 to 47·2) 9·9 (0·8 to 32·2) 1·68 (0·82 to 3·47) 1·75 (0·84 to 3·65)
≥2 cerebral microbleeds 8/341 23·4 (10·1 to 46·2) 8·4 (−0·5 to 25·8) 1·56 (0·73 to 3·35) 1·32 (0·60 to 2·93)
Data are calculated on the 1447 participants with follow-up data available. *Calculated as number of events/patient-years. †Adjusted for age and hypertension for symptomatic 
intracranial haemorrhage, and adjusted for age, sex, hypertension, diabetes, previous ischaemic stroke, and age-related white matter hyperintensities score for recurrent ischaemic 
stroke.
Table 3: Absolute event rates, absolute risks, and univariable and multivariable hazard ratios for symptomatic intracranial haemorrhage and recurrent 
ischaemic stroke during follow-up, according to baseline presence and burden of cerebral microbleeds
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over-interpretation. Thus, although we found that the 
rate of symptomatic intracranial haemorrhage increased 
as cerebral microbleed burden increased (and the rate of 
recurrent ischaemic stroke remained stable), we could 
not establish whether a cerebral microbleed burden 
threshold exists at which the absolute event rate of 
intracranial haemorrhage exceeds that of ischaemic 
stroke (ie, where anticoagulation might be associated 
with net harm as judged by absolute event rates). We 
found that having a single cerebral microbleed was not 
associated with a higher hazard of symptomatic 
intracranial haemorrhage, possibly because one cerebral 
microbleed reflects only minor small vessel disease, or 
because of limited inter-rater and intra-rater reliability 
for one cerebral microbleed.14,30
Most currently available bleeding risk scores (which 
include clinical risk factors but not neuroimaging 
biomarkers) show only modest predictive value for 
intracranial haemorrhage with C-indexes of about 0·5,31 
although a post-hoc analysis32 of the ROCKET-AF study 
suggested that including more detailed quantitative 
factors (eg, platelet count, albumin, diastolic blood 
pressure) might also improve the predictive performance. 
Our findings suggest that adding cerebral microbleed 
presence as a neuroimaging biomarker to a widely used 
clinical risk score (HAS-BLED) might improve specificity 
and sensitivity in identifying ischaemic stroke and 
transient ischaemic attack patients at high risk of 
intracranial haemorrhage; this knowledge should allow 
better informed counselling, closer follow-up of high-risk 
individuals, rational anticoagulant choice, consideration 
of non-anticoagulant treatment options (eg, left atrial 
appendage occlusion), and more aggressive management 
of modifiable risk factors for intracranial haemorrhage 
(eg, hypertension, anticoagulant monitoring, and 
compliance). Large-scale collaborations are required to 
refine and validate robust risk prediction scores. Mean-
while, our findings suggest that future risk scores to 
identify patients with stroke at risk of intracranial 
haemorrhage should include cerebral microbleeds as a 
neuroimaging biomarker in addition to clinical 
parameters.
Our study has some important strengths. We 
prospectively studied a large inception cohort of patients 
at multiple hospital stroke units using predefined MRI 
sequences, rated for neuroimaging markers of small 
vessel disease using validated scales by a single trained 
observer. We followed up 97% of our cohort, and 
experienced observers adjudicated all primary events 
blinded to baseline cerebral microbleed presence. We 
undertook survival analysis to account for baseline 
confounding factors and varying follow-up, and followed 
a prespecified statistical analysis plan.
We also acknowledge our study’s limitations. Our cohort 
is likely to be affected by selection bias because patients 
with more severe strokes were less likely to be enrolled. 
Nevertheless, our cohort is likely to be representative of 
patients considered for anticoagulation soon after 
ischaemic stroke. All local investigators agreed to a policy 
of making anticoagulation decisions without considering 
cerebral microbleeds, but it was not possible to mandate 
and monitor blinding at the 79 participating centres. 
Although bias remains possible owing to the absence of 
formal blinding, 96% of all recruited patients with 
satisfactory MRI sequences were started on anticoagulants 
regardless of cerebral microbleed status. The proportion 
of DOAC use was similar in patients with cerebral 
microbleeds (40%) and without cerebral microbleeds (36%), 
suggesting that cerebral microbleeds did not influence the 
choice of VKA or DOAC. Because most participants in 
CROMIS-2 took VKA, our findings might not be 
generalisable to health-care settings where DOACs are the 
most widely used anticoagulant. Our study had a low rate 
of symptomatic intracranial haemorrhage, limiting our 
ability to adjust for multiple confounders, the robustness 
of our risk prediction models and, importantly, our ability 
to determine how increasing cerebral microbleed burden 
might relate to intracranial haemorrhage risk. Although 
we standardised parameters for MRI, different scanners 
with different magnetic field strengths were used, 
which can influence cerebral microbleed detection.33 
Furthermore, T2*-weighted GRE MRI sequences are less 
sensitive to cerebral microbleeds than is susceptibility-
weighted imaging,34 so our interpretation of cerebral 
microbleed-related risk might not generalise to 
susceptibility-weighted imaging data. Treatment decisions 
might be influenced by clinical nihilism about intracranial 
haemorrhage compared with ischaemic stroke; judgment 
of different apparent severities of incident intracranial 
haemorrhage compared with ischaemic stroke might in 
part be artefacts of clinical behaviour.
The low incidence of symptomatic intracranial 
haemorrhage in patients with ischaemic stroke or transient 
ischaemic attack anticoagulated for atrial fibrillation makes 
randomised controlled trials in this field challenging. 
However, large-scale international pooled collaborative 
observational cohort analyses should help to refine 
risk prediction and determine whether high cerebral 
microbleed counts might be associated with an increased 
risk of intracranial haemorrhage sufficient to clearly 
identify patients at risk of net harm from oral 
anticoagulation.
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